Christiana Stamoulis - 19 Dec 2025 Form 4 Insider Report for Keenova Therapeutics plc

Reporting relationship: President and CFO
Issuer ticker: N/A
Reported as of: 19 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 23 Dec 2025, 17:31:09 UTC
Prior SEC filing: 17 Dec 2025
Next SEC filing: 26 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Mark Tyndall, Attorney-in-Fact

Key filing fact

Christiana Stamoulis filed Form 4 for Keenova Therapeutics plc on 23 Dec 2025.

Key facts

This page summarizes Christiana Stamoulis's Form 4 filing for Keenova Therapeutics plc.
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 23 Dec 2025, 17:31.

Change

Previous filing in this sequence was filed on 17 Dec 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001502917 Primary reporting owner

Stamoulis Christiana

Relationship: President and CFO
Address: 675 MCDONNELL BLVD., HAZELWOOD
Signature: /s/ Mark Tyndall, Attorney-in-Fact
Signature date: 23 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

No ticker transaction

Ordinary Shares

Tax liability

Transaction value
Shares: -18,631
Change %: -51%
Price
Shares after: 17,828
Date: 19 Dec 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The number of ordinary shares withheld to satisfy tax withholding obligations arising out the vesting of restricted stock units ("RSUs"), which vested on December 15, 2025, is based on a percentage and did not take into account any market value as the Issuer's ordinary shares are not listed or quoted on a recognized trading market.

Footnote F2

The Reporting Person received 18,371 additional RSUs resulting from the adjustment of the RSUs held by the Reporting Person immediately prior to the separation of Par Health, Inc. ("Par Health") from the Issuer on November 10, 2025, pursuant to the terms of the Employee Matters Agreement by and between the Issuer and Par Health. As a result, the 30,335 RSUs that vested on December 15, 2025, were adjusted to 36,459 RSUs.

SEC remarks

This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.